Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • MJFF Research Grant, 2012
    Pre-clinical Safety Study of LRRK2 Inhibitors

    Objective/Rationale:             

    LRRK2 is well recognized as a potential central nervous system target for the treatment of Parkinson’s disease (PD).  For development as possible therapeutic drugs...

  • Resource: Utilizing DATATOP Biospecimens, 2012
    Small-molecule PD Biomarkers: a Metabolomic Analysis

    Objective/Rationale:             
    Based on our earlier findings that yielded several promising biomarkers, this metabolomic study of small-molecule biochemicals will investigate specimens from...

  • Dyskinesia LEAPS, 2012
    Xenon Inhalation to Reduce L-DOPA-Induced Dyskinesia

    Levodopa is the most effective drug to treat symptoms of Parkinson’s disease, however long-term use leads to disabling L-DOPA-induced dyskinesia (LID) in the vast majority of patients. NMDA receptor...

  • MJFF Research Grant, 2012
    Intrinsic Remodeling of the Fovea in Parkinson’s Disease

    Promising Outcomes of Original Grant:
    In the past we determined the part of the retina (the back of the eye) which needs to be measured for PD induced changes. We developed an equation which permits...

  • MJFF Research Grant, 2012
    Bay Area Solvent Study - Symptoms (BASS-S)

    Objective/Rationale:             
    Chlorinated solvents are commonly used in a variety of occupations. The solvents trichloroethylene (TCE) and perchloroethylene (PERC) have been associated with an...

  • Improving Levodopa Delivery, 2012
    Enhanced Dopamine Availability, Prolonged Activity and Improved Dyskinesia Profile After Administration of Selectively Deuterated Levodopa

    Objective/Rationale:
    To confirm the found beneficial effects of DP-102 (reduced dyskinetic effects at motoric equieffective doses in comparison to regular levodopa) in a pre-clinical model of Parkinson...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.